FDA Brief

Warning letters Drugs

FDA warning letter to

Anish S. Shah, M.D./Siyan Clinical Research

MediumIssued Dec 12, 2023Posted Dec 26, 2023Center for Drug Evaluation and Research | CDER

FDA warned clinical investigator Dr. Anish Shah that he broke blinding rules in a depression drug study, calling the site's data into question.

What happened

FDA inspected Dr. Shah's clinical site in Santa Rosa, California, from December 5 to December 16, 2022, as part of its Bioresearch Monitoring Program, which checks how human research is run. FDA found that Dr. Shah served as the "blinded" rater and completed 16 MADRS depression-rating assessments for all three enrolled subjects, even though he also saw those subjects' safety data (vital signs, lab reports, physical exams), which the protocol said the blinded rater must not see. FDA said his response to the inspection findings lacked enough detail on how the fixes would actually be carried out.

What FDA found

  1. Dr. Shah did not run the study the way the study plan (protocol) required.

    21 CFR 312.60
  2. The protocol required depression ratings to be done by a rater kept blind to safety data, but Dr. Shah did those ratings while also reviewing vital signs, lab reports and doing physical exams.

    21 CFR 312.60
  3. Dr. Shah did 16 MADRS assessments for all three subjects, at least five of the seven required per subject, as an unblinded assessor.

    21 CFR 312.60
  4. His written corrective action plan did not give enough detail for FDA to judge whether the fixes would prevent repeat problems.

What FDA wants

Within 15 business days of receiving the letter, Dr. Shah must write to FDA describing what he has done to prevent similar violations, with supporting documentation, or explain why he believes he was compliant.

Who should pay attention

  • sponsors running blinded central nervous system trials at this site
  • contract research organizations that select and monitor investigator sites
  • other clinical investigators who both rate efficacy and review safety data

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Smitha C. Reddy, M.D./ACRC Studies, LLC

    FDA warns Dr. Smitha Reddy over clinical trial protocol violations, including wrong drug given and broken blinding.

    High risk